Covered recipient · General Payments record
LORRAINE A GARLAND
Allopathic & Osteopathic Physicians Obstetrics & Gynecology
General Payments · PY2018–2021
$484.07
- Reported across 32 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2021 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $277.54 | 18 |
By paying entity
PY2021 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $104.49 | 7 |
| TherapeuticsMD, Inc. | $81.42 | 5 |
| PFIZER INC. | $45.49 | 3 |
| Evofem Biosciences, Inc. | $32.98 | 2 |
| Organon LLC | $13.16 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2021 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AbbVie Inc. | $11.07 | 01/05/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794555017 | CMS |
| AbbVie Inc. | $20.64 | 02/09/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794555021 | CMS |
| AbbVie Inc. | $13.18 | 03/10/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794555025 | CMS |
| AbbVie Inc. | $16.36 | 04/28/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794555029 | CMS |
| AbbVie Inc. | $13.91 | 06/01/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794555033 | CMS |
| AbbVie Inc. | $16.99 | 08/03/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794555037 | CMS |
| AbbVie Inc. | $12.34 | 09/07/2021 | Food and Beverage | Undisputed | 01/23/2026 | 794555041 | CMS |
| Evofem Biosciences, Inc. | $16.60 | 10/26/2021 | Food and Beverage | Undisputed | 01/23/2026 | 855180511 | CMS |
| Evofem Biosciences, Inc. | $16.38 | 12/14/2021 | Food and Beverage | Undisputed | 01/23/2026 | 855180509 | CMS |
| Organon LLC | $13.16 | 07/20/2021 | Food and Beverage | Undisputed | 01/23/2026 | 837204113 | CMS |
| PFIZER INC. | $14.70 | 04/13/2021 | Food and Beverage | Undisputed | 01/23/2026 | 832606833 | CMS |
| PFIZER INC. | $11.53 | 09/07/2021 | Food and Beverage | Undisputed | 01/23/2026 | 832884879 | CMS |
| PFIZER INC. | $19.26 | 11/16/2021 | Food and Beverage | Undisputed | 01/23/2026 | 833214951 | CMS |
| TherapeuticsMD, Inc. | $15.15 | 01/12/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844924267 | CMS |
| TherapeuticsMD, Inc. | $12.40 | 06/15/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844924271 | CMS |
| TherapeuticsMD, Inc. | $17.76 | 07/27/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844924279 | CMS |
| TherapeuticsMD, Inc. | $17.15 | 08/17/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844924283 | CMS |
| TherapeuticsMD, Inc. | $18.96 | 12/07/2021 | Food and Beverage | Undisputed | 01/23/2026 | 844924275 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021
- Generated from
- OP_DTL_GNRL_PGYR2021_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.